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Abstract
Objectives—To compare outcomes of antiretroviral therapy (ART) in South Africa, where viral
load monitoring is routine, with Malawi and Zambia, where monitoring is based on CD4 cell
counts.
Methods—We included 18,706 adult patients starting ART in South Africa and 80,937 patients
starting in Zambia or Malawi. We examined CD4 responses in models for repeated measures, and
the probability of switching to second-line regimens, mortality and loss to follow-up in multi-state
models, measuring time from six months.
Findings—In South Africa 9.8% (9.1–10.5%) had switched at 3 years, 1.3% (95% CI 0.9–1.6%)
remained on failing first-line regimens, 9.2% (8.5–9.8%) were lost to follow-up and 4.3% (3.9–
4.8%) had died. In Malawi and Zambia more patients were on a failing first-line regimen (3.7%,
3.6–3.9%), fewer patients had switched (2.1%, 2.0–2.3%) and more patients were lost (15.3%,
15.0–15.6%) or had died (6.3%, 6.0–6.5%). Median CD4 cell counts were lower in South Africa
at start of ART (93 vs. 132 cells/µL, p<0.001) but higher after 3 years (425 vs. 383 cells/µL,
p<0.001). The hazard ratio comparing South Africa with Malawi and Zambia, adjusted for age,
sex, first-line regimen and CD4 cell count, was 0.58 (95% CI 0.50–0.66) for death and 0.53 (0.48–
0.58) for loss to follow-up.
Conclusions—Over 3 years of ART mortality was lower in South Africa than in Malawi or
Zambia. The more favourable outcome in South Africa might be explained by viral load
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monitoring leading to earlier detection of treatment failure, adherence counselling and timelier
switching to second-line ART.
INTRODUCTION
The World Health Organization (WHO) estimates that over 5 million HIV-1 infected people
were receiving antiretroviral therapy (ART) in low- and middle-income countries by the end
of 2009 [1]. As access to HIV treatment continues to expand, more people are experiencing
treatment failure, and switching to second-line therapy is on the increase. Viral load
monitoring is typically not available in the public-sector in resource-limited settings: viral
load monitoring is expensive and the necessary laboratory infrastructure is difficult to
implement and maintain, particularly in rural areas.
In the absence of viral load monitoring, diagnosis of treatment failure relies on immunologic
(i.e. CD4 cell counts) and clinical criteria [2]. The ability of CD4 counts to predict virologic
failure is, however, limited: sensitivity and positive predictive value of the immunological
WHO criteria for virological treatment failure have been shown to be poor [3] [4]. Use of
these criteria may therefore lead to unnecessary switching to second-line ART among
patients with suppressed viral replication, or cause undue delays in switching among patients
with real – but undetected – virological failure.
In a recent analysis of 17 ART programmes in resource-limited settings we found that
patients with access to viral load monitoring were more likely to switch to second-line
therapy earlier and at higher CD4 cell counts than those enrolled in programmes without
viral load monitoring [5]. Delays in switching will increase the time on low CD4 cell counts,
and may promote the selection of resistant strains and thus affect long-term prognosis. In the
present study we analyzed data from treatment programmes in Southern Africa to compare
switching to second-line ART, loss to follow-up and mortality in the Republic of South
Africa (RSA), where viral load monitoring is routine, to outcomes in Zambia and Malawi,
where monitoring is based on CD4 cell counts.
METHODS
Antiretroviral treatment programmes
The International epidemiological Databases to Evaluate AIDS in Southern Africa (IeDEA-
SA) is a collaboration of ART programmes in Southern Africa [6]. Data are collected at
ART initiation (baseline) and each follow-up visit, using standardized instruments, and
transferred in regular intervals to data centres at the Universities of Cape Town, RSA and
Bern, Switzerland. All sites have ethical approval to collect data and participate in IeDEA-
SA.
We included four public-sector ART programmes from RSA, which monitor viral load and
CD4 cell counts every 3 to 6 months: Khayelitsha [7], Gugulethu [8] and the Tygerberg
clinic [9] in Cape Town, and the Themba Lethu clinic [10] in Johannesburg. The South
African programmes (‘viral load sites’) were compared with two treatment programmes
from Malawi and Zambia, which monitor CD4 cell counts but have only limited access to
viral load measurements (also referred to as ‘non viral load sites’): the Lighthouse clinic at
Kamuzu Central Hospital in Lilongwe [11] and the Ministry of Health - Centre for
Infectious Disease Research in Zambia (MoH-CIDRZ) programme in Lusaka [12, 13]. All
six programmes trace patients lost to follow-up. In Khayelitsha, patients lost to follow-up
who could not be contacted by telephone are visited at home by a clinic nurse. In Gugulethu,
patients are allocated a therapeutic counsellor who lives in the same community, visits
patients at home and provides counselling and adherence support. In Themba Lethu and
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Tygerberg patients are traced using mobile telephone contacts. The Lighthouse clinic and
the MoH-CIDRZ programme use community health workers to trace patients.
Eligibility criteria and definitions
We included all treatment naïve patients aged 16 years and older who started ART with a
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen and who had at least
one day of follow-up. We defined immunological failure as a decline in the CD4 cell count
to the baseline value or below, a decline of at least 50% from the highest count on treatment
or a persistent CD4 cell count below 100 cells/µL after six months of antiretroviral therapy
[2]. Virological failure was defined as a plasma HIV viral load value above 10,000 copies/
ml [2]. For both immunologic and virologic failure we required two consecutive values
within 12 months of each other meeting the criteria. For immunological failure the second
value had to be equal to or lower than the first.
A switch to a second-line ART regimen was defined as a change from the initial regimen to
a protease inhibitor (PI)-based regimen after at least six months of follow-up with a
simultaneous change in at least one nucleoside reverse transcriptase inhibitor (NRTI).
Clinical disease stage was defined as less advanced (CDC stage A/B or WHO stage I/II) or
advanced (CDC stage C or WHO stage III/IV). A patient was considered lost to follow-up
(LTFU) if the last visit was more than 12 months before the closure date for that site, with
the closure date defined as the most recent visit date recorded in the database for that site.
Only patients with at least 12 potential months of follow-up could therefore be lost to
follow-up.
Analyses of treatment outcomes
We plotted Kaplan-Meier curves to determine the probability of death from all causes,
measuring time from ART initiation. Differences between viral load and non-viral load
patients were compared using log-rank tests. We then built a multi-state model [14] to
compare probabilities of death, loss to follow-up and switching to second-line regimens
between viral load and non viral load programmes, measuring time from ART initiation.
After 6 months of ART, when treatment response is assessed, a patient may remain on a
non-failing first-line regimen or move to treatment failure (virological failure in sites with
routine viral load monitoring or immunologic failure in sites without routine viral load
monitoring), second-line ART, loss to follow-up or death (Figure 1). A patient failing first-
line therapy may remain on the failing regimen, switch to second-line ART, be lost to
follow-up or die. A patient switching may remain on the new regimen, be lost to follow-up
or die. Death and loss to follow-up are final (absorbing) states in the model [14].
We calculated hazard ratios (HRs) separately for the first 6 months of ART, and from 6
months to the end of follow-up. We present HRs for death and loss to follow-up, and for the
second period additionally for switching to second-line ART. We compared sites with and
without viral load monitoring, adjusting for age (per 10 years increase), sex, first-line
regimen, CD4 cell count (per 100 cell increase) and WHO clinical stage (WHO stage III and
IV versus stage I and II) at ART initiation in the first analysis, and for age, sex, first-line
regimen and CD4 cell count at 6 months in the second analysis. Four categories of first line
regimens were included in the model: lamivudine, stavudine and nevirapine (3TC/d4T/
NVP); lamivudine, zidovudine and nevirapine (3TC/ZDV/NVP); lamivudine, stavudine and
efavirenz (3TC/d4T/EFV) and lamivudine, zidovudine and efavirenz (3TC/ZDV/EFV) or
other. We imputed missing CD4 cell counts at baseline and 6 months, and missing WHO
clinical stage at baseline. Imputations were based on multinomial and linear regression
models with disease stage and CD4 count as dependent variables and site, age, sex, year of
starting ART, time to death and CD4 cell count (in case of missing clinical stage) or clinical
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stage (in case of missing CD4 count) as independent variables. Analyses were run on each
of 20 datasets; results were combined with Rubin’s rules [15]. In sensitivity analyses we
repeated the analyses dropping one cohort in turn and restricting analyses to patients with
complete data (complete-case analysis).
Analysis of CD4 cell counts over time
We used models for repeated measures to compare CD4 cell count trajectories between sites
with and without viral load monitoring. We constructed a multi-level model (CD4
measurements within patients) with a random intercept and slope for each patient,
transforming time to the square root and the natural logarithm of time (fractional polynomial
[2, (−0.5, ln)]), as described previously [16]. All patients with a baseline CD4 cell count and
at least one additional CD4 count were included. We again examined the influence of single
cohorts by repeating the analyses dropping one cohort in turn.
Non-HIV related mortality
We explored to what extent differences in HIV-free background mortality influenced results.
We obtained estimates of non-HIV-related mortality for the year 2004 (the last year for
which data were available) from the Global Burden of Disease Study [17][18]. We
compared the expected HIV-unrelated mortality between countries with and without viral
load monitoring. Briefly, the expected number of deaths due to causes other than HIV
between months 7 and 36 was calculated by multiplying the number of person-years by the
corresponding sex, age- (in 5-year age groups) and country-specific rates of HIV-free
mortality.
Data were analyzed using Stata software version 11 (College Station, Texas, USA) and R
version 2.10 (The R Development Core Team).
RESULTS
Patient and programme characteristics
A total of 99,643 patients met eligibility criteria and were included: 7,230 patients from
Khayelitsha, 2,658 patients from Gugulethu, 7,457 patients from Themba Lethu, 1,361
patients from Tygerberg, 9,604 patients from Lighthouse and 71,333 patients from MoH-
CIDRZ. Overall 18,706 patients were treated at sites with routine viral load monitoring in
RSA (27,288 person-years of follow-up) and 80,937 patients at sites without access to viral
load monitoring in Malawi and Zambia (147,876 person-years of follow-up). The proportion
of patients excluded because they were only seen once and had no follow-up was similar
across sites: 1.5% (range across sites 0.4–2.2%) in viral load sites and 1.3% (range 1.0–
3.6%) in non viral load sites.
Patients from viral load sites were more likely to be female (66% versus 62%) and had
lower CD4 cell counts (93 versus 132 cells/µL) at start of therapy (Table 1). In both settings
most patients started ART with a regimen that combined 3TC/d4T either with NVP or EFV.
AZT, didanosine (ddI) and boosted lopinavir (LPV/r) was the most common second-line
regimen in viral load sites whereas in CD4 sites a combination of tenofovir (TDF),
emtricitabine (FTC) and LPV/r was most commonly used. The South African programmes
had better access to diagnostic examinations and treatments than the programmes in Malawi
and Zambia, including availability of computer tomography, Cryptococcus neoformans
antigen testing, and first-line therapy for opportunistic infections. Further details on patient
characteristics and availability of diagnostic examinations are given in Webtable 1 and
Webtable 2.
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Of the eligible 99,643 patients, 3,009 (3.0%) failed their first-line regimen, 1,839 (1.8%),
switched to a second-line regimen, 13,547 patients (13.6%) were lost to follow-up, and
8,015 patients (8.0%) died during the first 3 years on ART. Figure 2 shows Kaplan–Meier
curves of the all-cause mortality for programmes with and without viral load monitoring.
Cumulative mortality was slightly higher in non viral load sites in the first 6 months of ART,
but curves crossed and separated thereafter, with higher mortality in non viral load sites than
in viral load sites (p<0.0001). When programmes were analyzed separately mortality was
highest from month 6 onwards in the two non viral load sites. Figure 3 shows the results of
the multi-state model from 6 months after starting ART, based on 84,564 patients with at
least 6 months of follow-up. At 3 years 1.3% (95% CI 0.9–1.6%) of patients were on a
failing first-line regimen in viral load sites, 9.8% (9.1–10.5%) had switched to second-line
ART, 9.2% (8.5–9.8%) were lost to follow-up and 4.3% (3.9–4.8%) had died. In non viral
load sites, more patients were on a failing first-line regimen (3.7%; 95% CI 3.6–3.9%),
fewer patients had switched (2.1%, 2.0–2.3%) and more patients were lost (15.3%, 15.0–
15.6%) or had died (6.3%, 6.0–6.5%). Estimates for different time points are given in
Webtable 3.
Table 2 shows crude and adjusted hazard ratios from multi-state models measuring time
from the start of ART to 6 months, and from 6 months to the end of follow-up. Mortality
was slightly lower in sites with viral load monitoring during the first six months on therapy
(adjusted HR 0.83, 95% CI 0.74–0.92), and substantially lower after the first six months
(adjusted HR 0.58, 0.50–0.66). Loss to follow-up was similar in the first six months; after
six months, however, the risk was lower in viral load sites (adjusted HR 0.53, 0.48–0.58).
Patients were more likely to switch to second-line ART in viral load compared to non viral
load sites (adjusted HR 4.16, 3.57–4.85). Results were similar in sensitivity analyses that
omitted one cohort in turn from the analysis (Webtable 4), and similar in the complete-case
analysis (Webtable 5).
CD4 cell counts over time
A CD4 count at baseline and at least one additional CD4 cell count during follow-up were
recorded for 8,981 (48.0%) patients from viral load sites and 42,587 (52.6%) patients from
non viral load sites. The 51,568 patients included in the analysis contributed a total of
257,636 CD4 counts. The median number of CD4 measurements was 4 (interquartile range
[IQR] 3–7) in both settings. Figure 4 shows 6-week moving averages of CD4 counts and
modelled CD4 trajectories by CD4 count at ART initiation. The trajectories crossed at six
months, with less pronounced increases in non viral load sites compared to viral load sites
thereafter. Table 3 shows CD4 cell count and viral load data at different time points for viral
load and non viral load sites. In viral load sites CD4 cell counts were lower initially, but
higher at virologic failure and at the start of second-line ART than in non viral load sites.
Three years after starting ART median CD4 cell counts were 425 cells/µL (IQR 308–582) in
viral load sites and 383 cells/µL (IQR 268–526) in non viral load sites (p<0.001). The
omission of one cohort in turn did not materially alter results (Webfigure 1).
Non-HIV related mortality
The expected non-HIV related mortality rate was 0.62 (95% CI 0.52–0.75) per 100 person-
years for the South African sites compared to 0.80 (0.75–0.85) per 100 person-years in
Zambia and Malawi. The crude observed mortality from 6 months to 3 years was 2.12
(1.93–2.34) and 3.10 (2.99–3.20) per 100 person-years, respectively. Differences in
background mortality could therefore explain about 20% of the observed mortality
difference. Details of calculations are presented in Webtable 6.
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We compared long-term outcomes of ART in four scale-up programmes in RSA, where
viral load is routinely monitored, with two programmes from Zambia and Malawi, where
only CD4 cell counts are regularly measured. Mortality was somewhat lower initially, and
substantially lower after 6 months on ART in viral load compared to non viral load sites. A
similar picture was seen for loss to follow-up, with lower rates of loss to follow-up in viral
load sites after 6 months. Comparisons of CD4 cell count trajectories were compatible with
the findings for mortality, with less pronounced increases in counts in non viral load sites
compared to viral load sites after 6 months. Finally, switching to second-line regimens was
more frequent in viral load sites. These results were robust in sensitivity analyses, and not
driven by a single cohort.
Our study was based on almost 100,000 adult patients from six public sector treatment
programmes in three countries. Results should thus be applicable to many other patients in a
region heavily affected by HIV. We acknowledge that the treatment programmes included in
this study will not be representative for all programmes in the three countries: they are
located in urban areas, equipped with electronic medical record systems, and have access to
regular CD4 cell determination and second-line therapy [19]. Information on stage of
disease and CD4 cell counts was missing in some patients, both in settings with and without
routine viral load monitoring. We used multiple imputations to account for the missing
information and followed recent guidelines when building these models [20]. We did not
examine clinical failure: not all sites systematically collect data on opportunistic infections
and diagnostic capabilities and criteria vary between sites. Also, we had no information on
adherence or drug resistance.
There is debate on the place of viral load monitoring for ART in resource-limited settings
[21, 22]. A modelling study of long-term ART concluded that the reduction in mortality
associated with viral load monitoring is small and cost-effectiveness poor [21]. A
randomized trial [23] compared 3-monthly monitoring of CD4 count with viral load
monitoring in Thailand and found that over three years switching was somewhat more
frequent with CD4 count monitoring compared to viral load monitoring (7.2% versus 5.1%,
p=0.10) and that mortality was similar (3.4% versus 4.3%, p=0.57). Modelling studies
assume that patients monitored by CD4 counts switch to second-line ART when meeting
criteria for immunological failure, and protocols of clinical trials ensure that this is the case.
The present study shows that the situation in practice is quite different: few patients switch
to second-line ART in programmes relying on CD4 counts to monitor ART in Malawi and
Zambia, and many more patients remain on a failing first-line regimen compared to
programmes monitoring viral load in RSA. Mortality in patients remaining on failing first-
line regimens is high: in a previous study of 11 ART programmes in sub-Saharan Africa we
found that mortality at 1 year was 4.2% (95% CI 2.2–7.8%) in patients who switched to a
second-line regimen but 11.7% (7.3–18.5%) in patients who remained on a failing first-line
regimen [5, 24].
Our results support the notion that routine viral load monitoring contributed to the lower
mortality in RSA. First, mortality curves and CD4 trajectories separated after six months,
when patients start to switch to second-line therapy and when in viral load sites the first viral
load data became available to identify patients for adherence interventions. Data from RSA
[25] and Thailand [26] showed that many patients with low-level viraemia (<1000 copies/
ml) suppress viral replication after targeted interventions to improve adherence. The
monitoring of viral load may thus promote adherence and retention in care [27], in addition
to detecting high-level virologic failure requiring second-line therapy. In non viral load sites
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targeted viral load monitoring was used in some patients: 37% of those starting second line
therapy had a viral load measurement.
Second, the higher mortality in programmes without viral load monitoring was not explained
by differences in patient characteristics at baseline. The median baseline CD4 cell count was
in fact lower in viral load than in non viral load sites. Third, switching to second-line ART
occurred later and at lower CD4 cell counts in programmes without viral load monitoring, in
line with a previous analysis of ART programmes in lower-income countries [5]. Switching
at lower CD4 counts is associated with higher mortality [24, 28]. Finally, at three years,
nearly three times as many patients were on a failing first-line regimen in non viral load
sites, compared to viral load sites. A study of patients initiating ART in several countries in
Asia also found a higher risk of disease progression in patients from sites with fewer than
one annual viral load [29]. A meta-analysis of cohort studies demonstrated that in patients
treated under WHO guidelines viral load monitoring was associated with reduced
probabilities of mutations conferring resistance to NNRTIs, the M184V/I mutation and,
thymidine analogue mutations (TAMS) [30].
This was an observational study and other factors than viral load monitoring could explain
our results. RSA is a middle-income country with a per capita Gross Domestic Product
(GDP) of $9,332 in 2009 whereas Zambia and Malawi are low-income countries who had
per capita GDP of $1,297 and $779, respectively, in the same year [31]. The ART
programmes in the latter two countries lacked access to diagnostic tests and treatments to
manage the complications of advanced HIV infection. In RSA resistance testing can be done
in programmes linked to an academic department, but not routinely: testing is generally
done in the context of research, or in complex cases of second-line failure.
We carefully considered programme attrition: a significant proportion of those lost to
follow-up may have died, particularly over the first year of therapy [32]. Analyses of
mortality were based on patients remaining in care, and uncounted deaths among patients
not returning to clinics could have introduced bias. After six months, patient attrition was
almost twice as common in non-viral sites compared to viral load sites: the bias associated
with loss to follow-up thus probably means that we underestimated mortality differences.
This bias will, however, be modest: fewer than 10% of patients were lost in the initial 6
months, and between 6 months and 3 years. In this situation the mortality observed among
patients retained in care will provide a reasonable estimate of programme-level mortality
[33].
In conclusion, over the first three years of ART, mortality, loss to follow-up and CD4
trajectories were more favourable among patients enrolled in programmes in RSA compared
to programmes in Malawi and Zambia. These differences may at least partly be explained by
more timely switching to second-line ART after virological failure in RSA and better
adherence counselling, where monitoring of viral load is routine.
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Refer to Web version on PubMed Central for supplementary material.
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States and transitions between states in the multi-state model.
ART= antiretroviral therapy
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Cumulative mortality of patients starting antiretroviral therapy in four sites with routine viral
load monitoring from the Republic of South Africa and two sites without access to routine
viral load monitoring in Malawi and Zambia.
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Cumulative probability of treatment outcomes from 6 months after starting antiretroviral
therapy in sites with and without routine viral load monitoring in the Southern Africa IeDEA
cohort.
Failure relates to virological failure in viral load sites and immunological failure in non viral
load sites and relates to patients who met criteria for failure but have not been switched to
second-line therapy.
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Evolution of CD4 cell counts from start of antiretroviral therapy (ART) up to three years
after start of ART in four sites with routine viral load (Republic of South Africa) and two
sites without access to viral load monitoring (Malawi and Zambia).
Lines represent the mean fit of the mixed effect model with 95% confidence intervals, dots
and crosses the moving averages of the observed data. Viral load sites are shown as broken
lines and dots, non viral load sites as solid line and crosses.
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Table 1
Patient characteristics in public-sector HIV treatment programmes with and without routine viral load
monitoring in the Southern Africa IeDEA cohort.
Variable Viral load sites





Women (%) 12,291 (65.7) 50,036 (61.8)
Median age [IQR] (years) 34 [30–41] 35 [30–42]
Clinical stage (%)
   Stage available 18,359 (98.1) 77,572 (95.8)
   Advanced * 10,601 (57.7) 54,878 (70.7)
CD4 cell count (cells/µL)
   CD4 count available 11,880 (63.5) 59,939 (74.1)
   Median [IQR] 93 [39–159] 132 [66–203]
HIV-1 viral load (copies/ml)
   Viral load available (%) 7,183 (38.4) 839 (1.0)
   Median log viral load [IQR] 5.0 [4.5–5.5]
   ≤ 10,000 805 (11.7%) 98 (11.7%)
   10,001–100,000 2626 (36.6%) 228 (27.2%)
First-line regimens (%)
   3TC d4T EFV 12, 231 (65.4) 4,970 (6.1)
   3TC ZDV EFV 954 (5.1) 2,756 (3.4)
   3TC d4T NVP 4,204 (22.5) 46,940 (58.0)
   3TC ZDV NVP 1,217 (6.5) 25,419 (31.4)
   Other 100 (0.5) 852 (1.1)
Second-line regimens (%)
   TNV FTC LPV/r 817 (59.7%)
   AZT ddI LPV/r 657 (73.1%)
   ABC ddI LPV/r 231 (16.9%)
   3TC AZT LPV/r 81 (9.0%)
   3TC AZT LPV/r TNV 59 (4.3%)
   3TC AZT EFV LPV/r 33 (3.7%)
   Other 128 (14.2%) 262 (19.1%)
Interquartile ranges (IQR) are shown in square brackets and percentages in brackets. ABC, abacavir; ddI, didanosine; EFV, efavirenz; d4T,
stavudine; FTC, emtricitabin; LPV, lopinavir; NVP, nevirapine; RTV: boost of ritonavir; 3TC, lamivudine; ZDV, zidovudine
*World Health Organization (WHO) stages III or IV.
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Table 2
Crude and adjusted hazard ratios for HIV treatment outcomes comparing antiretroviral treatment programmes
with and without (reference group) routine viral load monitoring in the Southern Africa IeDEA cohort.






From start of ART to 6 months
    All-cause mortality 0.97 (0.89–1.05) 0.43 0.83 (0.74–0.92) 0.002
    Loss to follow-up 1.37 (1.28–1.48) <0.001 1.00 (0.91–1.11) 0.39
From 6 months to end of follow-up
    All-cause mortality 0.65 (0.58–0.72) <0.001 0.58 (0.50–0.66) <0.001
    Loss to follow-up 0.56 (0.52–0.60) <0.001 0.53 (0.48–0.58) <0.001
    Switch to second-line ART 4.71 (4.24–5.24) <0.001 4.16 (3.57–4.85) <0.001
Results from multi-state models based on 20 imputed datasets.
*Adjusted for age, sex, first-line regimen, CD4 cell count and clinical stage at start of first line therapy and for age, sex, first-line regimen and CD4
cell count at 6 months.
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